Osecon (002755.SZ) issued an announcement. Jiangsu Aosaikang Pharmaceutical Co., Ltd., a subsidiary of the company (hereinafter referred to as...
Zhitong Finance App News, Osecon (002755.SZ) announced that the company's subsidiary Jiangsu Aosaikang Pharmaceutical Co., Ltd. (hereinafter referred to as the “subsidiary”) announced the first phase I (ASKC202-001) dose escalation clinical trial data for advanced solid tumors in the form of a poster at the American Association for Cancer Research (AACR) annual meeting on April 8, 2024.
In terms of safety and efficacy, ASKC202 has good tolerability and safety, and also shows deep tumor remission and continuous anti-tumor signals. The ASKC202 dose extension trial is ongoing, and the company will further explore ASKC202 to conduct clinical trials in combination with the third-generation EGFRTKI being developed by the company.
Currently, the highly selective cMet inhibitors on the market are all used to treat non-small cell lung cancer with Met14 exon jumping mutations, and no drugs have been approved to treat patients with cMet amplified tumors. The development of ASKC202 will further improve the company's anti-tumor product line, enhance the company's competitiveness and sustainable profitability, and play a positive role in the company's strategic layout.